ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
129.230,71
0,02%
S&P 500
5.177,68
-0,19%
US Dollar vs BRL
5,0897
0,29%
Bitcoin
62.464,95
0,21%
Brent Oil
83,165
0,36%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NYSE
  6. Invitae Corporation (NVTA)

  7. Invitae Corporation (NVTA) Notícias

NVTA

Invitae (NVTA)

Invitae Corporation
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NYSE:NVTA
DataHoraFonteTítuloCódigoCompanhia
06/03/202410:31Edgar (US Regulatory)Form 8-K - Current reportNYSE:NVTAInvitae Corporation
30/01/202409:00PR Newswire (US)Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease TherapeuticsNYSE:NVTAInvitae Corporation
29/01/202418:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NYSE:NVTAInvitae Corporation
24/01/202418:34Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NYSE:NVTAInvitae Corporation
22/01/202409:00PR Newswire (US)Invitae Completes Sale of Reproductive Health Assets to NateraNYSE:NVTAInvitae Corporation
21/12/202323:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:NVTAInvitae Corporation
13/12/202318:07PR Newswire (US)Invitae Divests Ciitizen Health Data Platform and Implements Further Cost CutsNYSE:NVTAInvitae Corporation
14/11/202321:55Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:NVTAInvitae Corporation
08/11/202318:36Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:NVTAInvitae Corporation
08/11/202318:01PR Newswire (US)Invitae Reports Third Quarter 2023 Financial ResultsNYSE:NVTAInvitae Corporation
06/11/202318:00PR Newswire (US)Invitae Launches Enhanced Chemistry of MRD Test to Better Serve Biopharmaceutical Clinical and Research PartnershipsNYSE:NVTAInvitae Corporation
01/11/202307:59PR Newswire (US)Invitae to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023NYSE:NVTAInvitae Corporation
25/10/202312:00PR Newswire (US)Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive ResultsNYSE:NVTAInvitae Corporation
19/10/202317:30PR Newswire (US)Invitae Appoints Dr. David Sholehvar as Chief Operating OfficerNYSE:NVTAInvitae Corporation
12/10/202317:15PR Newswire (US)Rural Hospital System Demonstrates the Clinical Benefits of Implementing Universal Hereditary Cancer Testing in Patients with Breast CancerNYSE:NVTAInvitae Corporation
10/10/202317:30PR Newswire (US)Invitae to Present Data at the National Society of Genetic Counselors 42nd Annual Conference That Supports Advancements in Medical GenomicsNYSE:NVTAInvitae Corporation
03/10/202313:07PR Newswire (US)Invitae's Common Hereditary Cancers Panel Receives FDA Market AuthorizationNYSE:NVTAInvitae Corporation
29/09/202321:00Dow Jones NewsFDA Gives Marketing Authorization to Invitae Test for Cancer GenesNYSE:NVTAInvitae Corporation
25/09/202317:30PR Newswire (US)Invitae Announces Appointment of Finance Veteran Ana Schrank as CFONYSE:NVTAInvitae Corporation
22/09/202317:30PR Newswire (US)Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing StandardNYSE:NVTAInvitae Corporation
28/08/202317:02PR Newswire (US)Invitae Hires Industry Veteran Robert Guigley as Chief Commercial OfficerNYSE:NVTAInvitae Corporation
15/08/202308:30PR Newswire (US)Clinical Trial Results Support Genetic Testing of All Patients with Prostate CancerNYSE:NVTAInvitae Corporation
14/08/202317:02PR Newswire (US)Invitae Announces Selection of Finance Executive Robert Dickey as Interim CFONYSE:NVTAInvitae Corporation
10/08/202317:03Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NYSE:NVTAInvitae Corporation
10/08/202301:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNYSE:NVTAInvitae Corporation
09/08/202310:22Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNYSE:NVTAInvitae Corporation
08/08/202317:01PR Newswire (US)Invitae Reports Second Quarter 2023 Financial ResultsNYSE:NVTAInvitae Corporation
26/07/202317:01PR Newswire (US)Invitae to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023NYSE:NVTAInvitae Corporation
03/07/202315:52Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:NVTAInvitae Corporation
15/06/202317:59Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:NVTAInvitae Corporation
 Apresentando as notícias mais relevantes sobre:NYSE:NVTA

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
AZEV4
AZEVEDO PN
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
ETER3
ETERNIT ON
BOV
COGN3
COGNA ON
BOV
VVEO3
CM Hospitalar ON
BOV
PRIO3
PETRORIO ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
CRFB3
CARREFOUR ON
BOV
SGPS3
SPRINGS ON
BOV
TELB4
TELEBRAS PN
BOV
NGRD3
Neogrid Participacoes ON
BOV
GFSA3
GAFISA ON
BOV
JHSF3
JHSF PART ON
BOV
ENAT3
ENAUTA ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados